FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review : press release : embargoed until: Friday, April 23, 2021, 7:00 p.m. ET

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.) ; United States. Food And Drug Administration.
• Description:
  Following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Janssen (Johnson & Johnson) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Vaccines, Synthetic Viral Vaccines
• Document Type:
  Press Release
• Name as Subject:
  Janssen COVID-19 vaccine
• Place as Subject:
  United States
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:8790461a4e36412864eb89081857b487c51cde8349279cacfcfe0df6ec36275a
• Download URL:
  https://stacks.cdc.gov/view/cdc/105457/cdc_105457_DS1.pdf
• File Type:
  [PDF - 90.94 KB ]